title: [Patient's care and management of dyslipidemia in type 2 diabetic patients in the clinical practice in Spain: The LIPEDIA study].
abstract: BACKGROUND
  Treatment of atherogenic dyslipidemia (AD) in type 2 diabetes (DM2) should focus on the global control of dyslipidemia. The aim of this study was to determine how hospital (MSs) and primary care specialist (GPs) from Spain manage AD in DM2 during their daily practice.
  
  
  METHODS
  An observational, cross-sectional, multicentric study was conducted. Information about daily practice was obtained from 497 MSs and 872 GPs across Spain.
  
  
  RESULTS
  66% of MSs and 30.5% of GPs considered DM2 patients to be high-risk. Most consider the c-LDL targets based on European guidelines. The statins most widely used are atorvastatin and simvastatin. However both MSs and GPs considered rosuvastatin to be the most appropriate statin for these patients. 82% of MSs and 68% of GPs considered that >50% of their patients achieved the c-LDL target. The main reasons of not achieving this target were lack of treatment adherence and pressure from the administration. Seventy four percent of MSs reported that there are no common clinical protocols with GPs.
  
  
  CONCLUSIONS
  The differences in the perception of the real cardiovascular risk of the patient, low use of more appropriate statins, lack of adherence and poor perception of real c-LDL control may contribute to the failure in achieving lipid targets in DM2.
authors.affiliation: Centro Salud Palleter, Castellón, España. Electronic address: pascual_vic@gva.es.
authors.forename: Vicente
authors.initials: V
authors.lastname: Pascual Fuster
authors.affiliation: Departamento Médico Ferrer, Barcelona, España. Electronic address: jruizo@ferrer.com.
authors.forename: Emilio
authors.initials: E
authors.lastname: Ruiz Olivar
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, CiberObn, Fipec, Idibell, Hospitalet de Llobregat, Barcelona, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pintò Sala
mesh_terms: D050197:Atherosclerosis / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D050171:Dyslipidemias / Q000188:drug therapy*; D019538:Health Care Surveys; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D012307:Risk Factors; D013030:Spain
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids
keywords: Atención primaria; Atherogenic dyslipidemia; Dislipemia aterogénica; Estatinas; Primary care; Statins